Proteomics discovery of biomarkers for mitral regurgitation caused by mitral valve prolapse

Journal of Proteomics

Volumn 94, Issue , 2013, Pages 337-345

  Tan, Hwee Tong ^a   Ling, Lieng H ^b,c   Dolor Torres, Maria Consolacion ^b   Yip, James Wei Luen ^c   Richards, Arthur Mark ^b   Chung, Maxey C M ^a,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Dept Medicine Endocrinol Diabet   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Biomarkers; Complement component C4b; Haptoglobin; Mitral regurgitation; Mitral valve prolapse; Platelet basic protein

Indexed keywords

BASIC PROTEIN; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C4B; FIBRONECTIN; HAPTOGLOBIN; THROMBOCYTE BASIC PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHEMICAL LABELING; COMBINATORIAL LIBRARY; COMBINATORIAL PEPTIDE LIGAND LIBRARY; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; ISOBARIC TAG FOR RELATIVE AND ABSOLUTE QUATITATION LABELING; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE PROLAPSE; MITRAL VALVE REGURGITATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS; REGULATORY MECHANISM; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

BIOMARKERS; COMPLEMENT COMPONENT C4B; HAPTOGLOBIN; MITRAL REGURGITATION; MITRAL VALVE PROLAPSE; PLATELET BASIC PROTEIN;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; MITRAL VALVE PROLAPSE; PROTEOME; PROTEOMICS;

EID: 84886530861     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.10.009     Document Type: Article

References (45)

1. Guy T.S., Hill A.C. Mitral valve prolapse. Annu Rev Med 2012, 63:277-292.
2. Ling L.H., Enriquez-Sarano M., Seward J.B., Tajik A.J., Schaff H.V., Bailey K.R., et al. Clinical outcome of mitral regurgitation due to flail leaflets. N Eng J Med 1996, 335:1417-1423.
3. Kang D.H., Kim J.H., Rim J.H., Kim M.J., Yun S.C., Song J.M., et al. Comparison of early surgery versus conventional treatment in asymptomatic severe mitral regurgitation. Circulation 2009, 119:797-804.
4. Biner S., Rafique A., Rafii F., Tolstrup K., Noorani O., Shiota T., et al. Reproducibility of proximal isovelocity surface area, vena contracta, and regurgitant jet area for assessment of mitral regurgitation severity. JACC Cardiovasc Imaging 2010, 3:235-243.
5. Vahanian A., Alfieri O., Andreotti F., Antunes M.J., Baron-Esquivias G., Baumgartner H., et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012, 33:2451-2496.
6. Pizarro R., Bazzino O.O., Oberti P.F., Falconi M., Achilli F., Arias A., et al. Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. J Am Coll Cardiol 2009, 54:1099-1106.
7. Edwards A.V., White M.Y., Cordwell S.J. The role of proteomics in clinical cardiovascular biomarker discovery. Mol Cell Proteomics 2008, 7:1824-1837.
8. Lathrop J.T., Anderson N.L., Anderson N.G., Hammond D.J. Therapeutic potential of the plasma proteome. Curr Opin Mol Ther 2003, 5:250-257.
9. Lacerda C.M., Disatian S., Orton E.C. Differential protein expression between normal, early-stage, and late-stage myxomatous mitral valves from dogs. Proteomics Clin Appl 2009, 3:1422-1429.
10. Adams D.H., Rosenhek R., Falk V. Degenerative mitral valve regurgitation: best practice revolution. Eur Heart J 2010, 31:1958-1966.
11. Di Girolamo F., Boschetti E., Chung M.C., Guadagni F., Righetti P.G. "Proteomineering" or not? The debate on biomarker discovery in sera continues. J Proteomics 2011, 74:589-594.
12. Tan H.T., Tan S., Lin Q., Lim T.K., Hew C.L., Chung M.C. Quantitative and temporal proteome analysis of butyrate-treated colorectal cancer cells. Mol Cell Proteomics 2008, 7:1174-1185.
13. Tan H.T., Lim T.K., Chung M.C., Lin Q. iTRAQ labeling coupled with LC-MALDI mass spectrometry for monitoring temporal response of colorectal cancer cells to butyrate treatment. Methods Mol Biol 2011, 716:207-224.
14. Kersey P.J., Duarte J., Williams A., Karavidopoulou Y., Birney E., Apweiler R. The International Protein Index: an integrated database for proteomics experiments. Proteomics 2004, 4:1985-1988.
15. Loei H., Tan H.T., Lim T.K., Lim K.H., So J.B., Yeoh K.G., et al. Mining the gastric cancer secretome: identification of GRN as a potential diagnostic marker for early gastric cancer. J Proteome Res 2012, 11:1759-1772.
16. Anderson N.L., Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:845-867.
17. Boschetti E., Righetti P.G. The ProteoMiner in the proteomic arena: a non-depleting tool for discovering low-abundance species. J Proteomics 2008, 71:255-264.
18. Karp N.A., Lilley K.S. Investigating sample pooling strategies for DIGE experiments to address biological variability. Proteomics 2009, 9:388-397.
19. Diz A.P., Truebano M., Skibinski D.O.F. The consequences of sample pooling in proteomics: an empirical study. Electrophoresis 2009, 30:2967-2975.
20. Levy A.P., Asleh R., Blum S., Levy N.S., Miller-Lotan R., Kalet-Litman S., et al. Haptoglobin: basic and clinical aspects. Antioxid Redox Signal 2010, 12:293-304.
21. Marchand A., Galen R.S., Van Lente F. The predictive value of serum haptoglobin in hemolytic disease. JAMA 1980, 243:1909-1911.
22. Yeo T.C., Freeman W.K., Schaff H.V., Orszulak T.A. Mechanisms of hemolysis after mitral valve repair: assessment by serial echocardiography. J Am Coll Cardiol 1998, 32:717-723.
23. Garcia M.J., Vandervoort P., Stewart W.J., Lytle B.W., Cosgrove D.M., Thomas J.D., et al. Mechanisms of hemolysis with mitral prosthetic regurgitation. Study using transesophageal echocardiography and fluid dynamic simulation. J Am Coll Cardiol 1996, 27:399-406.
24. Baggiolini M. Activation and recruitment of neutrophil leukocytes. Clin Exp Immunol 1995, 101(Suppl. 1):5-6.
25. Iida N., Haisa M., Igarashi A., Pencev D., Grotendorst G.R. Leukocyte-derived growth factor links the PDGF and CXC chemokine families of peptides. FASEB J 1996, 10:1336-1345.
26. Holt J.C., Niewiarowski S. Biochemistry of alpha granule proteins. Semin Hematol 1985, 22:151-163.
27. Tang Y.Q., Yeaman M.R., Selsted M.E. Antimicrobial peptides from human platelets. Infect Immun 2002, 70:6524-6533.
28. von Hundelshausen P., Petersen F., Brandt E. Platelet-derived chemokines in vascular biology. Thromb Haemost 2007, 97:704-713.
29. Nishimura R.A., McGoon M.D., Shub C., Miller F.A., Ilstrup D.M., Tajik A.J. Echocardiographically documented mitral-valve prolapse. Long-term follow-up of 237 patients. N Engl J Med 1985, 313:1305-1309.
30. Avierinos J.F., Gersh B.J., Melton L.J., Bailey K.R., Shub C., Nishimura R.A., et al. Natural history of asymptomatic mitral valve prolapse in the community. Circulation 2002, 106:1355-1361.
31. Walsh P.N., Kansu T.A., Corbett J.J., Savion P.J., Goldburgh W.P., Schatz N.J. Platelets, thromboembolism and mitral valve prolapse. Circulation 1981, 63:552-559.
32. Tse H.F., Lau C.P., Cheng G. Relation between mitral regurgitation and platelet activation. J Am Coll Cardiol 1997, 30:1813-1818.
33. Martini F., Zuppiroli A., Gori A., Chiarantini E., Fedi S., Prisco D., et al. Platelet and blood clotting activation in patients with mitral valve prolapse. Thromb Res 1996, 83:299-306.
34. Tanaka R., Yamane Y. Platelet aggregation in dogs with mitral valve regurgitation. Am J Vet Res 2000, 61:1248-1251.
35. Moesgaard S.G., Sorensen T.M., Sterup A., Tarnow I., Kristensen A.T., Jensen A.L., et al. Changes in platelet function in Dachshunds with early stages of myxomatous mitral valve disease. Res Vet Sci 2009, 86:320-324.
36. Tarnow I., Kristensen A.T., Texel H., Olsen L.H., Pedersen H.D. Decreased platelet function in Cavalier King Charles Spaniels with mitral valve regurgitation. J Vet Intern Med 2003, 17:680-686.
37. Tarnow I., Kristensen A.T., Olsen L.H., Falk T., Haubro L., Pedersen L.G., et al. Dogs with heart diseases causing turbulent high-velocity blood flow have changes in platelet function and von Willebrand factor multimer distribution. J Vet Intern Med 2005, 19:515-522.
38. Theroux P., Martel C. Complement activity and pharmacological inhibition in cardiovascular disease. Can J Cardiol 2006, 22:18B-24B. Suppl. B.
39. Szilagyi A., Fust G. Diseases associated with the low copy number of the C4B gene encoding C4, the fourth component of complement. Cytogenet Genome Res 2008, 123:118-130.
40. Blasko B., Kolka R., Thorbjornsdottir P., Sigurdarson S.T., Sigurdsson G., Ronai Z., et al. Low complement C4B gene copy number predicts short-term mortality after acute myocardial infarction. Int Immunol 2008, 20:31-37.
41. Tacke F., Zimmermann H.W., Trautwein C., Schnabl B. CXCL5 plasma levels decrease in patients with chronic liver disease. J Gastroenterol Hepatol 2011, 26:523-529.
42. Ebos J.M., Lee C.R., Bogdanovic E., Alami J., Van Slyke P., Francia G., et al. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 2008, 68:521-529.
43. Neal C.S., Michael M.Z., Pimlott L.K., Yong T.Y., Li J.Y., Gleadle J.M. Circulating microRNA expression is reduced in chronic kidney disease. Nephrol Dial Transplant 2011, 26:3794-3802.
44. Zhang X., Chen S., Li L., Wang Q., Le W. Decreased level of 5-methyltetrahydrofolate: a potential biomarker for pre-symptomatic amyotrophic lateral sclerosis. J Neurol Sci 2010, 293:102-105.
45. Mochel F., Charles P., Seguin F., Barritault J., Coussieu C., Perin L., et al. Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One 2007, 2:e647.